Selected Publications

Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systems.

Continuous cell lines from the Muscovy duck as potential replacement for primary cells in the production of avian vaccines.

Impaired antiviral response of adenovirus-transformed cell lines supports virus replication.

Purification of modified vaccinia virus Ankara from suspension cell culture.

Boosting Upstream, Downstream Processing: To Expedite Biomanufacturing, Deploy a New Genotype of Modified Vaccinia Virus Ankara.   

The avian cell line AGE1.CR.pIX characterized by metabolic flux analysis.

Propagation of viruses infecting waterfowl on continuous cell lines of Muscovy duck (Cairina moschata) origin.

Matrix and backstage: cellular substrates for viral vaccines

High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells.

Pharmaceutical Cell Lines for Biologics Production: Manipulation of cell growth, metabolism and product quality attributes

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara

Continuous influenza virus production in cell culture shows a periodic accumulation of defective interfering particles.

A novel genotype of MVA that efficiently replicates in single cell suspensions.

A genotype of modified vaccinia Ankara (MVA) that facilitates replication in suspension cultures in chemically defined medium.

Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells.

Production of a Viral-Vectored Vaccine Candidate Against Tuberculosis.

A chemically defined production process for highly attenuated poxviruses.

New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation.

An avian cell line designed for production of highly attenuated viruses.

Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin.

An avian cell line designed for production of highly attenuated viruses.

An Avian Designer Cell Line for Vaccine Manufacture.

CD26/DPP4 cell-surface expression in bat cells correlates with bat cell susceptibility to Middle East respiratory syndrome coronavirus (MERS-CoV) infection and evolution of persistent infection.

Influenza A Virus Polymerase Is a Site for Adaptive Changes During Experimental Evolution in Bat Cells.

Establishment of fruit bat cells (Rousettus aegyptiacus) as a model system for the investigation of filoviral infection.

Cell lines from the Egyptian fruit bat are permissive for modified vaccinia Ankara.

The influence of cell growth and enzyme activity changes on intracellular metabolite dynamics in AGE1.HN.AAT cells.

N-glycosylation and biological activity of recombinant human alpha1-antitrypsin expressed in a novel human neuronal cell line.

Quercetin treatment changes fluxes in the primary metabolism and increases culture longevity and recombinant α1-antitrypsin production in human AGE1.HN cells.

Quantitative characterization of metabolism and metabolic shifts during growth of the new human cell line AGE1.HN using time resolved metabolic flux analysis

Towards a 21st-century roadmap for biomedical research and drug discovery: consensus report and recommendations.

Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing.

Modeling Human Immunity In Vitro: Improving Artificial Lymph Node Physiology by Stromal Cells

Human immunity in vitro - Solving immunogenicity and more.

Crosstalk between immune cells and mesenchymal stromal cells in a 3D bioreactor system.

Engineering tissue alternatives to animals: applying tissue engineering to basic research and safety testing.

Immunological substance testing on human lymphatic micro-organoids in vitro.

A Human Lymph Node In Vitro – Challenges and Progress

Increasing antibody yield and modulating final product quality using the FreedomTM CHO-STM production platform.

Alternative Strategies and New Cell Lines for High-level Production of Biopharmaceuticals

Mammalian cells

A novel bicistronic gene design couples stable cell line selection with a fucose switch in a designer CHO host to produce native and afucosylated glycoform antibodies.

Engineering of CHO Cells for the Production of Recombinant Glycoprotein Vaccines with Xylosylated N-glycans.

Fucose-targeted glycoengineering of pharmaceutical cell lines.

Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase.

Characterization of Recombinant Proteins (Chapter 9.)

Quantitative MALDI-TOF-MS Using Stable-isotope Labeling: Application to the Analysis of N-glycans of Recombinant α-1 Antitrypsin Produced Using Different Culture Parameters.

Quality for Biologics.

Standardization, evaluation and early-phase method validation of an analytical scheme for batch-consistency N-glycosylation analysis of recombinant produced glycoproteins.

Drug Testing In Vitro – Breakthroughs and Trends in Cell Culture Technology.

Development and Assessment of Human Adenovirus Type 11 as a Gene Transfer Vector.

Genome Size and Structure Determine Efficiency of Postinternalizytion Steps and Gene Transfer of Capsid-Modified Adenovirus Vectors in a Cell-Type-Specific Manner.

The complete nucleotide sequence, genome organization, and orign of human adenovirus type11.

State-of-the-Art and New Optionsto Assess T Cell  Activation by Skin Sensitizers: Cosmetics Europe Workshop

Novel Bioreactors for Fragile Glycoproteins.